<div id="readability-page-1"><div>NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”)(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Replimune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until September 22, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Replimune securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. [Click here for information about joining the class action] On July 22, 2025, Replimune issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.” Per the press release, “[t] he CRL indicates that the FDA is unable to approve the application in its present form. The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness. Furthermore, the FDA said the trial cannot be adequately interpreted due to the heterogeneity of the patient population. The CRL also states that there are items related to the confirmatory trial study design which need to be addressed, including contribution of components. Importantly, no safety issues were raised.” On this news, Replimune’s stock price fell $9.52 per share, or 77.24%, to close at $2.81 per share on July 22, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP dpeyton@pomlaw.com 646-581-9980 ext. 7980 <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeE1ERXpOU00zTURreU56TTJJekl3TVRjMk5EUT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeE1ERXpOU00zTURreU56TTJJekl3TVRjMk5EUT0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGQ5OTY0YzYtNzQ0YS00NTgwLWFmMjQtNTBiMjdmNjJjZGZiLTEwMjkyMTctMjAyNS0wOC0xNy1lbg==/tiny/Pomerantz-LLP.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGQ5OTY0YzYtNzQ0YS00NTgwLWFmMjQtNTBiMjdmNjJjZGZiLTEwMjkyMTctMjAyNS0wOC0xNy1lbg==/tiny/Pomerantz-LLP.png"/></div></div>

REPL

Pomerantz 律師事務所已對 Replimune Group, Inc.（納斯達克代碼：REPL）提起集體訴訟，指控其涉嫌證券欺詐。遭受損失的投資者被鼓勵在 2025 年 9 月 22 日之前聯繫該事務所，以申請成為首席原告。該訴訟是在 FDA 就 Replimune 的 RP1 生物製品許可證申請發出完整回應函後，股價大幅下跌的背景下提起的，導致 2025 年 7 月 22 日股價下跌了 77.24%

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL